In addition, we suggest inhibiting DNMT1 and UHRF1 as promising therapeutic strategy for increasing the efficiency of leukemic cell differentiation to treat AML with differentiation therapy agents. This evidence concerns the gene DNMT1 and acute myeloid leukemia.